ArticleJournal of the American Heart Association2021
Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.Scientific reports · 2024Trial
- Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial.BMJ (Clinical research ed.) · 2024Trial
- Time- and risk-dependent effects of dual antiplatelet therapy targeting the P2Y12 receptor after CABG: A network meta-analysis of graft permeability and clinical outcomes.Journal of thrombosis and thrombolysis · 2026Article
- Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world.Cardiovascular drugs and therapy · 2026Article
- Modern Era in Personalized Medicine of Dual Antiplatelet Therapy After Myocardial Revascularization.Journal of clinical medicine · 2026Review
- Article
- Effect of P2Y12 Inhibitors on Major Adverse Cardiovascular Events After Coronary Artery Bypass Graft Surgery: A Population-Based Cohort Study.Pharmacotherapy · 2025Article
- Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update.JACC. Asia · 2025Review
- Antithrombotic management in an elderly CABG patient with nephrotic syndrome: a case report.Frontiers in cardiovascular medicine · 2025Article
- In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression.Balkan journal of medical genetics : BJMG · 2024Article
- Antithrombotic strategies for preventing graft failure in coronary artery bypass graft.Journal of thrombosis and thrombolysis · 2024Review
- The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk.Current cardiology reports · 2023Review
- Coagulation and Transfusion Updates From 2021.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.Journal of the American Heart Association · 2021Article
- Safety Comparison of Monotherapy Aspirin to Dual Antiplatelet Therapy Following Coronary Artery Bypass Surgery.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The optimal antiplatelet therapy after coronary artery bypass grafting remains unclear. We evaluated the association of dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin and clinical outcomes among patients undergoing coronary artery bypass grafting. Methods and Results A total of 18 069 consecutive patients who underwent primary isolated coronary artery bypass grafting between 2013 and 2017 were identified from a contemporary registry, and 10 854 (60.1%) received DAPT with clopidogrel plus aspirin as determined by claimed prescriptions after surgery. Cox regression models with inverse probability of treatment weighting were used to examine the associations between DAPT and outcomes. Patients who received DAPT, compared with those who received aspirin monotherapy, had a lower incidence of a composite of all-cause death, myocardial infarction, stroke, or repeat revascularization at 6 months (2.9% versus 4.2%; inverse probability of treatment weighting-adjusted hazard ratio [HR], 0.65; 95% CI, 0.55-0.77;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.